VIFOR-PHARMA
31.8.2021 07:02:05 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa® .
With regard to iron deficiency, the following new recommendations for HF patients with reduced function of the heart are added:
- Periodic screening for iron deficiency is recommended in all HF patients (Class I).
- Ferinject® should be considered to reduce the risk of HF hospitalizations in symptomatic HF patients with iron deficiency (Class IIa).
- Ferinject® should be considered before and early after discharge in patients who have been hospitalized with acute heart failure and with iron deficiency to improve HF symptoms and reduce risk of re-hospitalizations (Class IIa).
The existing recommendation to consider Ferinject® in patients with HF and iron deficiency to alleviate HF symptoms, improve exercise capacity and quality of life remains unchanged (Class IIa designation). The results of the AFFIRM-AHF study are reflected in the update of the ESC guidelines. Ferinject® remains the only intravenous (i.v.) iron therapy specifically mentioned in the new ESC HF guidelines.
The guidelines also propose that the use of potassium binder agents like Veltassa® may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients. In patients with chronic or recurrent hyperkalemia on RAAS inhibitor therapy Veltassa® may as well be initiated to maintain the patients on guidelines recommended doses of RAAS inhibitors. The new proposals further describe the unique evidence for RAASi enabling generated by Veltassa® through the clinical trials.
“We are very pleased with the new recommendations to the ESC’s guidelines in heart failure and are grateful for this development for the patients,” commented Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “With improved diagnosis rates of iron deficiency and enabling RAASi, more patients can benefit from treatment. Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure. We are particularly pleased by the consideration of Ferinject® and Veltassa® in the new treatment guidelines to achieve these therapeutic goals and believe this will enable us to further expand our role in helping heart failure patients with iron deficiency and hyperkalemia live better, healthier lives.”
The ESC HF guidelines aim to provide practical, evidence-based recommendations for the diagnosis and treatment of HF, thereby improving and harmonizing standards of diagnosis and treatment of cardiovascular diseases for physicians, and potentially optimizing patient care. The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.
The 2021 ESC guidelines are published under: www.escardio.org/Guidelines
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About AFFIRM-AHF
The AFFIRM-AHF study was a multi-center, randomized, double-blind, placebo-controlled trial, comparing the effect of intravenous ferric carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for acute heart failure. The study demonstrated that administration of Ferinject®
reduced the risk of HF hospitalizations and improved quality of life with no apparent effect on the risk of cardiovascular death.
About Ferinject®
Ferinject®
/Injectafer®
(ferric carboxymaltose) is a leading i.v. iron therapy with market authorization in 84 countries by the end of June 2021. More than 16 million patient years of experience have helped to establish Ferinject®
/ Injectafer®
as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2
.
About Veltassa®
Veltassa®
(patiromer) is a potassium binder approved for the treatment of hyperkalemia. Veltassa®
was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium. Veltassa®
should not replace emergency treatment for life-threatening hyperkalemia.
References:
1
Anker, S.,D. (2018). Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient meta-analysis. Eur J Heart fail. 20(1):125-133. doi: 1002/ejhf.823.
2
Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005519/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Draslovka to Acquire ex-Natron Energy Battery IP, Completing a Vertically Integrated Western Sodium-Ion Value Chain29.10.2026 14:30:00 CET | Press release
Acquisition gives Draslovka control of former Natron Energy IP portfolio spanning sodium-ion materials, cells and complete battery systems. Deal combines acquired IP with Draslovka’s existing chemistry and European cathode-material capabilities, bringing key parts of the sodium-ion value chain together within one Western-aligned group and its partners. The IP acquisition strengthens Draslovka’s position across the emerging Western sodium-ion battery value chain. Technology targets applications where safety, high power, long cycle life and performance across a wide temperature range are critical, including data centers, grid storage, defense, industrial fleets, telecoms, rail and aviation. The acquired IP will substantively boost Draslovka’s technology offering, a portfolio of transformative and protected innovations for specific industries. Draslovka’s US-based subsidiary, COVORO MINING SOLUTIONS LLC (Covoro), the operator of one of the largest solid sodium cyanide plants in the world,
Veracode Finds First Meaningful Gain in AI Code Security Since 2025 as Average Pass Rate Hits 62%29.10.2026 14:27:00 CET | Press release
October 2026 Study: Anthropic’s Claude Opus 5.5 and OpenAI’s GPT-6-Sol Jointly Lead at a Record 73%, Breaking the Previous High of 68% Veracode, the global leader in application risk management, today announced a jump from 56 percent to 62 percent in overall AI-generated code security, alongside a drop in vulnerabilities from 44 percent to 38 percent — the most significant improvement since the GenAI Code Security Report series began in July 2025. Anthropic's Claude Opus 5.5 and OpenAI's GPT-6-Sol co-lead the rankings at 73 percent, surpassing the previous high of 68 percent set by GPT-5.5 in July 2026. “We’ve been analysing code generated by multiple LLMs for more than a year. Until now, we have not seen a marked improvement in AI code security, despite consistently near-perfect functionality,” said Chris Wysopal, Co-founder & Chief Security Evangelist at Veracode. “This is the first time since running our study that we’ve been able to report a meaningful move on the security dial. Te
LeBron James Deepens Commitment to WHOOP, Expanding 11-Year Relationship29.10.2026 14:00:00 CET | Press release
One of the first 100 WHOOP members, James strengthens his commitment to the human performance company as the two partner to advance the future of performance, health, and longevity. WHOOP, the human performance brand, today announced that basketball legend LeBron James has joined as a global ambassador, formalizing a relationship that began more than a decade ago. One of the company's earliest members and now an investor, James will partner with WHOOP to champion the importance of sustained athletic excellence and everyday vitality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029868502/en/ LeBron James Deepens Commitment to WHOOP, Expanding 11-Year Relationship James began wearing WHOOP in 2015, long before continuous health monitoring became mainstream. Today, on the 23rd anniversary of his NBA debut, the 41-year-old continues to compete at the highest level of professional basketball. His decision to formalize the pa
Xsolla Acquires GamePix to Build a Complete Platform for Web and AI-Created Video Games29.10.2026 14:00:00 CET | Press release
GamePix’s Web Publishing and Distribution Join Xsolla’s Global Commerce Infrastructure, Giving Developers One Path From Video Game to Players Worldwide Xsolla, a global commerce company, today announced it acquired GamePix, the web games platform that publishes and distributes browser games worldwide. GamePix brings a catalog of 10,000+ web titles, a community of 4,000+ developers, and a publishing solution that brings any game to your web browser, from PC and mobile titles ported with its own technology to video games built with AI. Xsolla adds this commerce infrastructure to monetize those video games across 200+ geographies. Together, they give developers a single path from a finished video game to a paying, global audience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021024495/en/ Graphic: Xsolla Edouard Wawra, Valerio Pullano and Justine Silipo founded GamePix in 2013, when web games still ran on Flash. Since then
IFCO Demonstrates Sustainability Leadership by Combining Record Environmental Performance With Business Growth29.10.2026 13:38:00 CET | Press release
IFCO’s ESG Report 2026 highlights 833k metric tons of carbon emissions avoided in customer supply chains and a record 2.6 billion reusable packaging trips. IFCO, a global leader in reusable packaging solutions for fresh food, today published its ESG Report 2026. The report covers July 1, 2025, to June 30, 2026 and marks the first year of reporting against IFCO's Thriving with Purpose 2030 ESG strategy. During fiscal year 2026, the company managed an impressive 2.6 billion reusable packaging container (RPC) trips while reducing material greenhouse gas emissions by 11%. At the same time, customers using IFCO RPCs avoided 832,970 metric tons of CO₂e emissions, an increase of 13% compared with the previous year. Michael Pooley, CEO of IFCO: "The first year of our Thriving with Purpose 2030 ESG strategy showed that growth and sustainability go hand in hand. By expanding our network, investing in IFCO Digital, and scaling our circular model for reusable transport packaging, we are building a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom